6 completed, 6 unknown, 4 terminated, 3 active not recruiting. 10 Phase 2, 4 Phase 1, 3 Not applicable, 2 Phase 3.
Follow Muscle Invasive Bladder Cancer: new trials by email Literature Review of Muscle Invasive Bladder Cancer trials Research Report on Muscle Invasive Bladder Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer Radiochemotherapy, Radical cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Not yet recruiting | Brazilian Clinical Research Institute | 336 | 2026-06-01 | 2026-02-12 |
| Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy Neoadjuvant Chemotherapy, Radical Cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Recruiting | Assiut University | 76 | 2025-09-01 | 2025-10-02 |
| Sample Collection for Ongoing Research and Product Evaluation Study Breast Cancer, Lung Cancer | Recruiting | Natera, Inc. | 9600 | 2025-07-21 | 2026-01-15 | |
| Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer Rutin, Gemcitabine, Cisplatin, Tislelizumab - Muscle Invasive Bladder Cancer | Phase 1 | Recruiting | First Affiliated Hospital of Chongqing Medical University | 10 | 2025-05-01 | 2025-04-10 |
| Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients gemcitabine + cisplatine - Mibc, Muscle Invasive Bladder Cancer | Phase 2 | Not yet recruiting | Fundación de investigación HM | 70 | 2024-12-01 | 2024-10-04 |
| Clinical Performance Evaluation of the C2i Test C2i-WGS-MRD Test - Muscle Invasive Bladder Cancer | Withdrawn | University of Texas Southwestern Medical Center | 2024-08-01 | 2024-09-25 | ||
| Multiparametric MRI for Bladder Cancer: Validation of VI-RADS for the Detection of Muscle Invasive Bladder Cancer Magnetic resonance imaging - Multiparametric, Magnetic Resonance Imaging | Completed | Ain Shams University | 60 | 2024-08-01 | 2026-05-11 | |
| RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression | Phase 2 | Unknown | RenJi Hospital | 6 | 2023-08-01 | 2023-08-31 |
| To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC). Discrete Choice Experiment (DCE) Patients DCE Questionnaire, Semi-Structured Interview Patients Interview - Muscle Invasive Bladder Cancer, Surgery | Unknown | King's College London | 60 | 2022-07-20 | 2023-03-08 | |
| A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer APL-1202 in combination with tislelizumab, Tislelizumab alone - Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | Unknown | Jiangsu Yahong Meditech Co., Ltd aka Asieris | 79 | 2021-12-28 | 2022-02-22 |
| Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 712 | 2021-08-05 | 2026-06-04 |
| Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma Tislelizumab, Nab paclitaxel - Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 48 | 2020-07-11 | 2022-11-30 |
| A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Score on MRI Muscle Invasive Bladder Cancer | Completed | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 139 | 2020-01-01 | 2025-02-04 | |
| Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer pegylated liposomal doxorubicin (PLD), PD-1 - Muscle Invasive Bladder Cancer | Phase 2 | Unknown | Tianjin Medical University Second Hospital | 60 | 2019-09-17 | 2019-09-26 |
| Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma dose dense MVAC with pegylated GCSF - Muscle Invasive Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | Pusan National University Yangsan Hospital | 24 | 2019-05-01 | 2026-09-18 |
| A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Durvalumab, Oleclumab - Muscle Invasive Bladder Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 12 | 2019-02-20 | 2022-09-13 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer Avelumab, Radiation - Bladder Cancer, Muscle Invasive Bladder Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 14 | 2018-12-13 | 2025-10-31 |
| Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC Durvalumab, Cisplatin, Gemcitabine - Muscle Invasive Bladder Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1063 | 2018-11-16 | 2026-10-15 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy Nivolumab, Cisplatin, Gemcitabine - Muscle Invasive Bladder Cancer | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 43 | 2018-01-29 | 2021-12-16 |
Showing 20 of 25. Sign in to see all of them.
Urinary Bladder Neoplasms (8) · Carcinoma, Transitional Cell (3) · Breast Neoplasms (1) · Head and Neck Neoplasms (1) · Hematuria (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Patient Preference (1) · Patient Satisfaction (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1)
Neoplasms (11) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Neoplasms by Site (9) · Urogenital Neoplasms (9) · Urologic Diseases (9) · Urinary Bladder Diseases (8) · Urologic Neoplasms (8) · Neoplasms by Histologic Type (4) · Carcinoma (3) · Neoplasms, Glandular and Epithelial (3) · Adnexal Diseases (1) · Behavior (1)
Cisplatin (4) · Cystectomy (4) · Gemcitabine (4) · durvalumab (4) · tislelizumab (3) · Chemoradiotherapy (2) · Radiation (2) · AZD 6244 (1) · AZD4547 (1) · Doxorubicin (1) · Magnetic Resonance Spectroscopy (1) · Methotrexate (1) · Neoadjuvant Therapy (1) · Nivolumab (1) · Pilot Projects (1)
AstraZeneca (3) · Dana-Farber Cancer Institute (2) · Tianjin Medical University Second Hospital (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Brazilian Clinical Research Institute (1) · First Affiliated Hospital of Chongqing Medical University (1) · Fox Chase Cancer Center (1) · Fundación de investigación HM (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institut Bergonié (1) · Jiangsu Yahong Meditech Co., Ltd aka Asieris (1) · King's College London (1) · Masonic Cancer Center, University of Minnesota (1)
United States (11) · France (6) · China (5) · Spain (5) · United Kingdom (5) · Italy (4) · Brazil (3) · Canada (3) · Germany (3) · South Korea (3) · Chile (2) · Egypt (2) · Israel (2) · Japan (2) · Netherlands (2)
Amr Darwish, Lecturer (1) · Badrinath Konety, MD, MBA (1) · Elizabeth Plimack, MD (1) · Haige Chen (1) · Hailong Hu, MD,PhD (1) · Hendrik-Tobias Arkenau, MD, PhD (1) · Kent Mouw, MD, PhD (1) · Kwonoh Park, MD, PhD (1) · Riccardo Schiavina, MD (1) · Shilpa Gupta, MD (1) · Simon Hughes (1) · Thomas Powles, MBBS, MRCP, MD (1) · Xiao X Wei, MD (1) · Xin Gou, Professor (1) · Yair Lotan, MD (1)
PMID 24821881, PMID 11352955, PMID 11600601, PMID 12586807, PMID 12771730, PMID 12944571, PMID 15939524, PMID 16034041, PMID 21502557, PMID 24373477, PMID 24472710, PMID 24669010, PMID 24821883, PMID 25257030, PMID 26205531, PMID 26421586, PMID 27053504, PMID 28625005, PMID 29329894, PMID 32203306, PMID 34030643, PMID 35101381, PMID 37880682, PMID 37965307, PMID 39282910, PMID 40774226, PMID 42639047
2015 (1), 2017 (1), 2018 (1), 2023 (1), UL1TR001120 (1)